Vincristine Sulfate: The Microtubule-Targeting Chemotherapy Agent Revolutionizing Oncology
1. What is Vincristine?
Vincristine sulfate is a dimeric Catharanthus alkaloid derived from the Madagascar periwinkle (Catharanthus roseus). As a microtubule-disrupting agent, it binds with high affinity to β-tubulin at the vinca domain, inhibiting microtubule polymerization and disrupting mitotic spindle assembly. This triggers metaphase arrest و apoptosis in rapidly dividing cells. Classified as a WHO Essential Medicine, it’s clinically indispensable for treating acute leukemias, lymphomas, and solid tumors through its potent antimitotic activity.
2. Source, Chemical Properties & Identifiers
-
مصدر: Isolated from Catharanthus roseus leaves; semi-synthesized from precursors catharanthine and vindoline
-
الخصائص الكيميائية:
-
Chemical Name: Methyl (2β,3β,4β,5α,12β,19α)-15-[(5S,9S)-5-ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate sulfate
-
Molecular Formula: C₄₆H₅₆N₄O₁₀·H₂SO₄
-
Molecular Weight: 923.04 g/mol
-
مظهر: White to off-white hygroscopic powder
-
الذوبان: Freely soluble in water (30 mg/mL), sparingly soluble in ethanol
-
Stability: Light-sensitive; degrades above pH 5.5
-
-
Key Identifiers:
-
CAS: 2068-78-2 (vincristine sulfate)
-
EC Number (EINECS): 218-216-0
-
MF: C₄₆H₅₈N₄O₁₄S
-
MW: 923.04
-
3. Pharmaceutical-Grade Specifications & Clinical Profile
-
Optimal Product: Requires >99.5% HPLC purity, <0.1% vinblastine (toxic analog), and endotoxin-free (<0.25 EU/mg). Shaanxi Zhonghong achieves this through countercurrent chromatography و lyophilization stabilization.
-
Therapeutic Applications:
-
Oncology: First-line for ALL (induction therapy), Hodgkin/non-Hodgkin lymphoma, neuroblastoma, Wilm’s tumor
-
الآلية: Binds tubulin dimer (Kd=85 nM) → suppresses microtubule dynamics → mitotic catastrophe
-
(Note: Nattokinase demonstrates fibrinolytic activity; no clinical evidence supports nephroprotective benefits)
-
-
Dosage:
-
IV Administration Only: 1.4-2.0 mg/m² weekly (max 2 mg/dose)
-
No oral bioavailability; never self-administer
-
-
Critical Safety Profile:
-
Neurotoxicity: Dose-limiting peripheral neuropathy (sensory > motor)
-
Hematologic: Mild myelosuppression (unlike vinblastine)
-
Autonomic Effects: Ileus, bladder atony, orthostatic hypotension
-
Extravasation Risk: Severe tissue necrosis requiring central line
-
موانع الاستعمال: Charcot-Marie-Tooth disease, intrathecal administration (fatal)
-
4. Shaanxi Zhonghong: cGMP Vinca Alkaloid Specialist
With 28+ years in plant-derived oncology APIs, we produce EP/USP-compliant vincristine sulfate:
-
Scientific Infrastructure:
-
5 University Joint Labs (Tubulin binding research)
-
Patented Tech: CN202310XXXXXX (Vindoline stabilization)
-
-
Analytical Capabilities:
-
UPLC-MS/MS (purity/impurities)
-
600MHz NMR (structural confirmation)
-
ICP-MS (elemental impurities)
-
LAL Chromogenic (endotoxins)
-
-
Global Distribution: API shipments to 80+ countries with cold-chain compliance
5. Pharmaceutical Quality Specifications
فئة | المعلمة | مواصفة | Method |
---|---|---|---|
المبيدات الحشرية | الكلوربيريفوس | ≤0.01 mg/kg | كروماتوغرافيا الغاز-مطياف الكتلة/مطياف الكتلة |
Dimethoate | ≤0.02 mg/kg | LC-MS/MS | |
المعادن الثقيلة | Pb | ≤1.0 ppm | ICP-MS (USP <232>) |
Cd | ≤0.5 ppm | ICP-MS | |
علم الأحياء الدقيقة | TAMC | ≤10² CFU/g | جامعة ساو باولو <61> |
الإشريكية القولونية | Absent/10g | جامعة ساو باولو <62> | |
Critical Attributes | Vincristine Sulfate | ≥99.5% | HPLC-PDA (USP <621>) |
فينبلاستين | ≤0.1% | UPLC-MS | |
Water Content | ≤4.0% | Karl Fischer | |
Endotoxins | <0.25 EU/mg | LAL (USP <85>) |
6. cGMP Manufacturing Process
-
Botanical Sourcing: C. roseus cultivated under GACP guidelines
-
Alkaloid Extraction: Ethanol/water gradient extraction (pH 4.0)
-
Precursor Isolation: Ion-exchange chromatography (vindoline)
-
Oxidative Coupling: Fe³⁺/H₂O₂-mediated dimerization
-
Sulfation: Reaction with SO₃-pyridine complex
-
بلورة: Controlled polymorph formation (Form II crystals)
-
التجميد بالتجميد: -50°C freeze-drying under nitrogen atmosphere
-
Sterile Filtration: 0.22 µm membrane filtration
7. Clinical & Research Applications
-
Oncology Protocols:
-
R-CHOP (lymphoma)
-
VDCLP (pediatric ALL)
-
-
Drug Delivery Systems:
-
Liposomal encapsulation (Marqibo®)
-
Peptide-drug conjugates (tumor-targeted delivery)
-
-
Neuroscience Research:
-
Axonal transport studies
-
Neurotoxicity modeling
-
8. cGMP Quality Control Protocol
Zhonghong’s 360° QC includes:
-
Identity: ¹³C NMR (C-18/C-19 carbonyl resonance at 175.2 ppm)
-
Purity: HPLC-ELSD quantifies vincristine (≥99.5%) and vinblastine (≤0.1%)
-
Potency: Tubulin polymerization assay (IC₅₀ 0.1-0.3 μM)
-
Safety: Bacterial endotoxins (kinetic chromogenic LAL), sterility testing (USP <71>)
-
Stability: 24-month shelf-life at 2-8°C (ICH Q1A validated)
9. Cold-Chain Packaging & Logistics
-
Primary Container: Type I amber vials (nitrogen headspace)
-
التغليف الثانوي: Vacuum-sealed Alu-PET pouches with desiccant
-
تخزين: 2-8°C protected from light
-
Shipping: Global cold-chain transport (2-8°C) via DHL Thermonet
10. Mechanism & Innovations
-
Molecular Action:
-
High-affinity binding to βIII-tubulin isotype
-
Suppresses microtubule dynamic instability by 95%
-
Induces Bim-mediated apoptosis
-
-
Zhonghong Innovations:
-
Enzymatic dimerization (yield ↑35%)
-
Cryogenic milling for particle size control
-
-
Research Frontiers:
-
Tubulin isotype-specific analogs
-
Neuroprotective co-administration (glutamate antagonists)
-
-
التحديات:
-
Neurotoxicity management
-
ABC transporter-mediated resistance
-
11. FAQ
Q1: Can vincristine be used as a dietary supplement?
A: Absolutely not. Vincristine is a cytotoxic chemotherapy agent requiring medical supervision. Unauthorized use causes severe neurotoxicity.
Q2: Does nattokinase benefit kidney patients?
*A: No clinical evidence supports nattokinase for kidney disease. Vincristine requires dose adjustment in renal impairment (CrCl <30 mL/min).*
Q3: Why is vinblastine impurity controlled?
*A: Vinblastine causes distinct myelotoxicity. Our UPLC-MS detects ≤0.05% impurity (ICH Q3A limits).*
Q4: What distinguishes Zhonghong’s vincristine?
*A: cGMP manufacturing, ≥99.5% purity, endotoxin control (<0.25 EU/mg), and patented lyophilization technology.*
Q5: Do you supply vincristine for ADCs?
*A: Yes. GMP-grade maleimide-activated vincristine available for antibody-drug conjugates (DAR 4-8).*
12. Global Procurement
Source cGMP vincristine sulfate:
✉️ بريد إلكتروني: liaodaohai@gmail.com
🌐 Web: www.aiherba.com
Request: COA, DMF, regulatory support, and custom synthesis options.
13. Conclusion
Vincristine sulfate remains a cornerstone of pediatric and hematologic oncology with unique microtubule-targeting properties. Its clinical utility depends on ultra-high purity (>99.5%), stringent neurotoxic impurity control، و temperature-managed distribution. Shaanxi Zhonghong combines three decades of vinca alkaloid expertise, patented stabilization technology، و cGMP compliance to deliver APIs meeting global pharmacopeial standards. Partner with us for uncompromising quality in cancer therapeutics.
14. References
-
Noble RL, et al. (1958). J Am Chem Soc. 80:3487. [DOI:10.1021/ja01546a092]
-
Jordan MA, et al. (1985). J Biol Chem. 260:14608. [PMID:2995464]
-
WHO EML (2023): Vincristine sulfate injection
-
USP Monograph: Vincristine Sulfate. USP44-NF39
-
EMA Guideline CPMP/QWP/1850/04
-
Lobert S, et al. (1996). Biochemistry. 35:6806. [DOI:10.1021/bi952483n]
-
Zhonghong Patent: CN202310XXXXXX (Cryo-milling process)
-
ICH Q3D (R2): Elemental Impurities
-
FDA Label: Vincristine Sulfate Injection
-
Gidding CEM, et al. (1999). Cancer Chemother Pharmacol. 44:266. [DOI:10.1007/s002800050976]
المراجعات
لا توجد مراجعات بعد.